Sun Pharma shares rise despite a 36% drop in quarterly profit
Sun Pharma shares gained 0.87% on Friday even as September-quarter net profit fell 36.36%. Revenue rose 11.9%, according to Moody's report.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of Sun Pharmaceutical Industries closed up 0.87% at Rs 1,778.25 on the BSE on Friday, despite a 36.36% year-on-year fall in consolidated net profit for the September quarter. Profit came in at Rs 1,988.53 crore versus Rs 3,124.95 crore a year earlier. The drop was mainly due to exceptional costs linked to the proposed Organon acquisition and US litigation.
Revenue still grew 11.9% to Rs 16,198.71 crore. Domestic formulation sales in India rose 17.3%, while sales of global innovative medicines increased 6.9% to about $356 million. Total expenses climbed to Rs 12,287.83 crore.
The company said the Organon deal remains on track for completion by early 2027, subject to the remaining customary closing conditions. Brokerage Choice Institutional Equities kept its 'Buy' rating with an unchanged target price of Rs 2,300.
why it matters
Operating figures matter alongside the headline profit: EBITDA rose 4.8%, but its margin narrowed to 29.3%. Choice expects weakness in the US business, where lenalidomide erosion is a drag, to be partly offset by growth in India and emerging markets.
market impact
Sun Pharma stock: revenue and Indian growth support the shares, while one-off costs weigh on profit
- Sun Pharma shares mixed — weaker profit from one-off costs offset by revenue and Indian sales growth
tags
instruments
sources
- Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price — Moody's, 1 November 2026 at 15:19 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗